AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03991416 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postnatal care as usual
Description: In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
Study NCT01907880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: 4mg IV every 4 weeks for 3 cycles
Study NCT01907880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT03625791 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Description: 1 tube with 4 ml of blood per patient
Study NCT02583828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg
Study NCT02583828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5 mg
Study NCT05331872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stem cell infusion
Description: Human umbilical cord-derived mesenchymal stem cell infusion in the management of adult liver cirrhosis
Study NCT02162082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent or scaffold
Description: implantation of a CE certified drug-eluting stent, bare-metal stent or scaffold
Study NCT05960669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D model guided secondary resection
Description: A prostate model was 3D printed from preoperative pelvic MRI data and used during robot-assisted radical prostatectomy to mark a positive surgical margin and guide secondary resection.
Study NCT00033540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 650 mg/m\^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days
Study NCT02092142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q fever Vaccine
Description: Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
Study NCT04265027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg BIA 9 1067
Description: Hard Capsule; Oral
Study NCT00033540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m\^2, intravenous (IV) over 100 minutes, Days 1,8, every 21 days
Study NCT00873379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: melatonin
Description: one half of a 1 mg tablet of GNC rapid dissolving Melatonin, NPN (natural product number) 80001380, available over the counter in Canada
Study NCT00873379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: half a white placebo tablet
Study NCT03366103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given PO
Study NCT03366103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistusertib
Description: Given PO
Study NCT02272751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The Exercise intervention will consist of aerobic activity followed by upper and lower limb resistance training using Therabands and some core exercises.
Study NCT02272751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: The Relaxation intervention will consist of a chair-based program incorporating breathing exercises, meditation, visualisation and progressive muscle relaxation.
Study NCT01371149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surface parasternal electromyography (EMG) set up
Description: Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
Study NCT04265027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg BIA9 1067
Description: Hard Capsule; Oral
Study NCT04753554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ORI group
Description: The patient group whose oxygenation will be managed by ORI values. Hyperoxia or hypoxia will be prevented by using also blood gas analysis in critically ill patients.
Study NCT04265027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg Ongentys
Description: Hard Capsule; Oral
Study NCT04265027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Ongentys
Description: Hard Capsule; Oral
Study NCT01804413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegvisomant
Description: Pegvisomant 1 mg/kg injection 3 days before the glucagon test.
Study NCT01804413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin
Description: 0.1-0.15 units/kg
Study NCT04753554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORI group
Description: The patient group whose oxygenation will be managed by ORI values. Hyperoxia or hypoxia will be prevented by using also blood gas analysis in critically ill patients.
Study NCT04753554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional group
Description: In this patient group oxygenation will be managed as usual, using blood gas analysis.
Study NCT02822131 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: sodium phosphate
Study NCT02822131 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sevelamer, sodium bicarbonate, sodium chloride
Study NCT01361074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In Vivo Exposure for Animal Phobia following Öst´s guidelines
Description: In vivo exposure is applied using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). Exposure is conducted in a single extended session lasting up to 3 hours and implemented individually. The treatment includes participant modelling, in vivo exposure, reinforced practice and cognitive challenge. Treatment in a single session is just a starting point; it is recommended that the participants continue to be exposed to the phobic situations after therapy in their daily lives in order to fully surmount their problems. Participants are informed that the treatment required close collaboration between themselves and the therapist. The exposure session is completed in a gradual and planned way.
Study NCT01361074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality Exposure for Animal Phobia following Öst´s guidelines
Description: Augmented Reality (AR) is a variation of Virtual Reality in which the user sees the real world augmented by various virtual elements; it complements reality rather than replacing it completely (Azuma et al., 2001). The most significant aspect of AR is that the virtual elements add relevant and helpful information to the physical information available in the real world. The system includes the options of changing the number, movement and size of small animals. Preliminary data show the utility of the system for the treatment of insect phobia (Botella et al., 2005). AR exposure is applied in the same way than in vivo exposure, that is, in a gradual, planned and controlled way using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). The therapist can see what the participant sees in AR on a monitor and observe the same stimuli.
Study NCT04832906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal Oral Tablet
Description: A selective progesterone receptor modulator (SPRM), as a medical line of treatment for uterine fibroids. Due to its selective anti-proliferative and pro-apoptotic action, Ulipristal Acetate (UA) is assumed to be effective in reducing abnormal uterine bleeding (AUB) and fibroid size.
Study NCT04832906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine artery embolization
Description: Selective embolization of uterine arteries bilaterally, using polyvinyl alcohol (PVA) particles administered via a catheter followed by capping with a plug of gelatin sponge. The end point for embolization is to have a static column of contrast in the uterine artery, with only a stump filling when the internal iliac artery was injected.
Study NCT02531633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
Study NCT01050374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albendazole + praziquantel
Description: albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)
Study NCT01050374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mebendazole + praziquantel
Description: mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)
Study NCT02531633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match sirukumab
Description: Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
Study NCT03265756 — intervention group
Intervention type: DEVICE
Intervention: Multimometer
Description: A device for measuring respiration rate, temperature, heart rate and the degree of blood oxygenation of children
Study NCT02531633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
Study NCT03647111 — intervention group
Intervention type: DRUG
Intervention: Crizotinib
Description: Crizotinib 250mg po bid
Study NCT01133275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone therapy for 6 cycles (24 weeks).
Study NCT01133275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide therapy for 6 cycles (24 weeks).
Study NCT02531633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
Study NCT00048815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Established Selective Serotonin Reuptake Inhibitor antidepressant
Study NCT00048815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. John's Wort
Description: Natural extract from the St. John's Wort plant.
Study NCT00048815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo pill
Study NCT01028716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01028716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SQ
Study NCT01028716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01028716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT01028716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo PBSC
Study NCT01028716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC
Study NCT01028716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT01028716 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total-body irradiation (TBI)
Study NCT04284618 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: assessment of standardized and off axis view radiographs
Description: Radiographic assessment of hallux valgus interphalangeus angles is performed on preoperative standing anteroposterior and on off axis view radiographs. These radiographs are taken by equalizing the hyperpronation of the greater toe.
Study NCT04520256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Platform for Social Support & Friendly Competition
Description: An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.
Study NCT03413098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal CPAP mask
Description: Investigative Nasal Mask to be used for OSA therapy
Study NCT04338724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1002
Description: The dose levels will be escalated following a modified 3+3 dose escalation scheme.
Study NCT03694392 — intervention group
Intervention type: BIOLOGICAL
Intervention: Flublok Quadrivalent
Description: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs.
Study NCT03694392 — intervention group
Intervention type: BIOLOGICAL
Intervention: Standard Dose Inactivated Influenza Vaccine (SD-IIV)
Description: For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent.
Study NCT00495521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Aminosalicylic acid extended release granules
Description: Granules for oral administration will be administered as a volume equivalent to 50 mg/kg of 4-aminosalicylic acid three times daily for 2 weeks followed by 2 times daily for 2 weeks in the active arm or a comparable volume in the placebo arm
Study NCT00495521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4-Aminosalicylic acid extended release granules
Description: Granules for oral administration will be administered as a volume equivalent to 50 mg/kg of 4-aminosalicylic acid three times daily for 2 weeks followed by 2 times daily for 2 weeks in the active arm or a comparable volume in the placebo arm
Study NCT03509493 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FibriCheck
Description: Digital health application
Study NCT00224055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Ferric Gluconate Complex in Sucrose Injection
Description: Sodium Ferric Gluconate Complex in Sucrose Injection (Ferrlecit®), 250 mg IV weekly for 4 weeks
Study NCT00224055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate tablets
Description: ferrous sulfate, 325 mg oral, three times daily for 6 weeks
Study NCT01154283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)
Description: Noninvasive positive airway pressure ventilation
Study NCT01154283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)
Description: Noninvasive positive airway pressure ventilation
Study NCT00042432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cinacalcet (AMG 073)
Description: Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.
Study NCT00042432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinacalcet (AMG 073)
Description: Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.
Study NCT04599868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Patients will be assessed hourly for pulse and blood pressure, contraction frequency, vaginal bleeding. With strict monitoring for symptoms of magnesium sulfate toxicity.~All patients will receive dexamethasone to enhance fetal lung maturity. Rhesus factor status will be determined for all patients, . Hb level will be measured and anemic patients will receive correction by blood transfusion Cervical length will be measured after 24 h\& 48 h from administration of magnesium sulfate in both groups Maternal serum magnesium will be measured at admission and after 4 hours ,12 hours and 24 hours after administration of magnesium sulfate Patients of both groups will be assessed for their neonatal outcomes include deaths and gestational age at delivery, fetal birth weight. Apgar score at five minutes, neonatal intensive care unit admission and duration of admission and neonatal calcium level at time of delivery will be also assessed.
Study NCT01173029 — intervention group
Intervention type: DRUG
Intervention: Anti-hypertensive drug treatment
Description: Anti-hypertensive drug treatment was non-investigational. Drug regimen, including which drug and the number of drugs prescribed, was left at discretion of the physician who carried primary assistance.
Study NCT02775110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Natalizumab discontinuation
Description: Patients will be randomized to one of two groups: The Immediate Discontinuation Group (stop natalizumab immediately and continue with new DMT 1 month afterward) and the Taper-off Group (two additional infusions of natalizumab, one at 6 weeks and the next at 8 weeks following discontinuation. A new DMT will be initiated within 2 months of final natalizumab infusion).
Study NCT02775110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natalizumab discontinuation
Description: Patients will be randomized to one of two groups: The Immediate Discontinuation Group (stop natalizumab immediately and continue with new DMT 1 month afterward) and the Taper-off Group (two additional infusions of natalizumab, one at 6 weeks and the next at 8 weeks following discontinuation. A new DMT will be initiated within 2 months of final natalizumab infusion).
Study NCT00826358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-143
Description: Once, please see Arm Description for more details.
Study NCT00826358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: Once, see Arm Description for more detail
Study NCT00826358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: once, see Arm Description for more detail
Study NCT00276094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene 30 mg
Description: 1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
Study NCT00276094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg
Description: 1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
Study NCT00276094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
Study NCT00276094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nonhormonal vaginal lubricant
Description: Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
Study NCT00276094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nonhormonal vaginal lubricant
Description: Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
Study NCT04373499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Teach to Goal
Description: Virtual Teach-to-Goal is an educational module that teaches children how to use their inhaler properly; this is done with an IPAD. In the module, the child will complete a series of questions as a pre-assessment, watch a video about how to use the inhaler properly, and then answer a series of questions as a post-assessment. If a child answers any questions incorrectly, they will watch the video again and have another chance to answer the incorrect questions. The child will receive instruction by video one or multiple times (up to 3 times), depending on how much they understand after each round of instruction, as demonstrated by their responses to questions.
Study NCT04373499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Intervention
Description: There is a handout that describes proper inhaler technique. The RA reads the handout to the child.
Study NCT01869361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Study drug
Study NCT01869361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control drug
Study NCT01480609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retigabine / Ezogabine
Description: Retigabine / Ezogabine will be available as immediate release tablets of 50 milligrams strength. Subjects will be administered the tablet will 250 milliliters of water
Study NCT03617575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: apo-Lactoferrin
Description: 1.41 g of apo-Lactoferrin will be given together with 1.42 mg FeSO4 (0.08 mg of iron naturally in apo-Lf \[total of 1.5 mg iron\]) in a maize porridge (extrinsically labeled)